Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation - Weitz, Jeffrey I; Connolly, Stuart J; Patel, Indravadan; Salazar, Daniel; Rohatagi, Shashank; Mendell, Jeanne; Kastrissios, Helen; Jin, Jianqing; Kunitada, Satoshi (Thrombosis and haemostasis, 2010)
Keywords: Administration, Oral; Aged; Alanine Transaminase - blood; Anticoagulants - administration & dosage; Anticoagulants - adverse effects; Anticoagulants - pharmacokinetics; Aspartate Aminotransferases; Atrial Fibrillation - blood; Atrial Fibrillation - complications; Atrial Fibrillation - drug therapy; Bilirubin - blood; Biomarkers - blood; Blood Coagulation - drug effects; Double-Blind Method; Europe, Eastern; Factor Xa - metabolism; Factor Xa Inhibitors; Female; Fibrin Fibrinogen Degradation Products - metabolism; Hemorrhage - chemically induced; Humans; International Normalized Ratio; Male; Middle Aged; Pyridines - administration & dosage; Pyridines - adverse effects; Pyridines - pharmacokinetics; Stroke - blood; Stroke - etiology; Stroke - prevention & control; Thiazoles - administration & dosage; Thiazoles - adverse effects; Thiazoles - pharmacokinetics; Time Factors; Treatment Outcome; United States; Warfarin - administration & dosage; Warfarin - adverse effects; Warfarin - pharmacokinetics